Literature DB >> 9316878

A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.

E S Messina1, R F Tyndale, E M Sellers.   

Abstract

Nicotine is primarily metabolized to cotinine by cytochromes P450 (CYPs). The degree of variation in the metabolism of nicotine to cotinine and the relative roles of the polymorphic enzymes CYP2A6 and CYP2D6 in this metabolism were investigated. The apparent K(m) and V(max) values (mean +/- S.D.) for cotinine formation in human liver microsomes (n = 31) were 64.9 +/- 32.7 microM and 28.1 +/- 28.7 nmol/mg of protein/hr, respectively. A 30-fold difference was seen among the individual V(max) values, with four livers showing significantly higher rates of cotinine formation. CYP2D6 is unimportant in nicotine metabolism because quinidine (a CYP2D6 inhibitor) had little effect on inhibition of cotinine formation; V(max) values for dextromethorphan (CYP2D6 probe substrate) and nicotine (n = 9) did not correlate (r = .49, P = .18), and a cDNA CYP2D6 expression system failed to metabolize nicotine to cotinine. CYP2A6 appears to be the major P450 involved in human nicotine metabolism to cotinine. Coumarin, a specific and selective CYP2A6 substrate, competitively inhibited cotinine formation by 85 +/- 11% (mean +/- S.D.) in 31 human livers. The K(i) value for this inhibition ranged from 1 to 5 microM, and a CYP2A6 monoclonal antibody inhibited cotinine formation by >75%. Immunochemically determined CYP2A6 correlated significantly with nicotine-to-cotinine V(max) values (r = .90, n = 30, P < .001) and to inhibition of nicotine metabolism by coumarin (r = .94, n = 30, P < .001). These data indicate that nicotine metabolism is highly variable among individual livers and that this is due to variable expression of CYP2A6, not CYP2D6.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316878

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  115 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 2.  Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.

Authors:  Laura L Hurley; Robert E Taylor; Yousef Tizabi
Journal:  Neurotox Res       Date:  2011-09-20       Impact factor: 3.911

3.  Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity.

Authors:  Dongmei Li; Xiaoqin Huang; Keli Han; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2011-04-22       Impact factor: 15.419

4.  Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation.

Authors:  Gary E Swan; Karen Suchanek Hudmon; Lisa M Jack; Kymberli Hemberger; Dorit Carmelli; Taline V Khroyan; Huijun Z Ring; Hyman Hops; Judy A Andrews; Elizabeth Tildesley; Dale McBride; Neal Benowitz; Chris Webster; Kirk C Wilhelmsen; Heidi S Feiler; Barbara Koenig; Lorraine Caron; Judy Illes; Li S-C Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

5.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 6.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

7.  Genetics and smoking.

Authors:  Anu Loukola; Jenni Hällfors; Tellervo Korhonen; Jaakko Kaprio
Journal:  Curr Addict Rep       Date:  2014-03-01

Review 8.  Pharmacogenetics and smoking cessation with nicotine replacement therapy.

Authors:  Riju Ray; Robert A Schnoll; Caryn Lerman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.

Authors:  Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox
Journal:  Addict Behav       Date:  2012-11-29       Impact factor: 3.913

10.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.